DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+3.45%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.35B
AUM Growth
+$3.35B
(-3.7%)
Cap. Flow
-$548M
Cap. Flow
% of AUM
-16.37%
Top 10 Holdings %
Top 10 Hldgs %
41.71%
Holding
75
New
10
Increased
22
Reduced
20
Closed
8
Top Buys
| 1 |
Immunovant
IMVT
|
$63.1M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$57.5M |
| 3 |
TG Therapeutics
TGTX
|
$51.1M |
| 4 |
Axsome Therapeutics
AXSM
|
$44.1M |
| 5 |
argenx
ARGX
|
$43M |
Top Sells
| 1 |
Insmed
INSM
|
$187M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$80.8M |
| 3 |
Geron
GERN
|
$74.2M |
| 4 |
Apogee Therapeutics
APGE
|
$52.1M |
| 5 |
Guardant Health
GH
|
$43.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
TG Therapeutics
TGTX
$5.03B
| $51.1M | 1.52% |
+2,870,131
| New | +$51.1M |
|
27
Viridian Therapeutics
VRDN
$1.59B
| $51M | 1.52% |
3,923,849
+467,796
| +14% | +$6.09M |
|
28
Kymera Therapeutics
KYMR
$3.1B
| $44.8M | 1.34% |
1,500,000
+237,754
| +19% | +$7.1M |
|
29
MindMed
MNMD
$689M
| $44M | 1.31% |
6,103,817
-562,850
| -8% | -$4.06M |
|
30
Olema Pharmaceuticals
OLMA
$432M
| $43.3M | 1.29% |
4,000,000
+774,581
| +24% | +$8.38M |
|
31
Terns Pharmaceuticals
TERN
$651M
| $41.5M | 1.24% |
6,100,000
| – | – |
|
32
Spyre Therapeutics
SYRE
$1.02B
| $41.3M | 1.23% |
1,756,667
+543,247
| +45% | +$12.8M |
|
|
33
Apogee Therapeutics
APGE
$2.27B
| $39.4M | 1.17% |
1,000,000
-1,323,456
| -57% | -$52.1M |
|
34
Structure Therapeutics
GPCR
$1.14B
| $37.3M | 1.11% |
950,000
+909,863
| +2,267% | +$35.7M |
|
35
ANI Pharmaceuticals
ANIP
$2.06B
| $29.7M | 0.89% |
466,089
-355,912
| -43% | -$22.7M |
|
36
Editas Medicine
EDIT
$225M
| $28M | 0.84% |
6,000,000
+472,710
| +9% | +$2.21M |
|
|
CLYM
37
Climb Bio, Inc. Common Stock
CLYM
$151M
| $27.8M | 0.83% |
+3,904,785
| New | +$27.8M |
|
38
HilleVax
HLVX
$105M
| $26.5M | 0.79% |
1,832,652
-739,808
| -29% | -$10.7M |
|
39
Korro Bio
KRRO
$244M
| $26.1M | 0.78% |
+770,645
| New | +$26.1M |
|
|
SLN
40
Silence Therapeutics
SLN
$237M
| $25.8M | 0.77% |
1,359,745
-284,136
| -17% | -$5.4M |
|
41
Nektar Therapeutics
NKTR
$543M
| $22.2M | 0.66% |
1,191,700
-34,967
| -3% | -$650K |
|
42
enGene Holdings
ENGN
$249M
| $21.2M | 0.63% |
2,250,000
| – | – |
|
43
Alector
ALEC
$282M
| $21M | 0.63% |
4,631,998
+862,612
| +23% | +$3.92M |
|
44
89bio
ETNB
$1.37B
| $18.4M | 0.55% |
+2,294,011
| New | +$18.4M |
|
45
Fate Therapeutics
FATE
$119M
| $18.3M | 0.55% |
5,572,607
| – | – |
|
46
Inovio Pharmaceuticals
INO
$144M
| $16.7M | 0.5% |
+2,066,720
| New | +$16.7M |
|
47
Praxis Precision Medicines
PRAX
$980M
| $16.1M | 0.48% |
+389,546
| New | +$16.1M |
|
|
CYBN
48
Cybin
CYBN
$142M
| $15.8M | 0.47% |
1,529,988
| – | – |
|
49
Context Therapeutics
CNTX
$75.6M
| $14.9M | 0.44% |
+7,419,355
| New | +$14.9M |
|
50
Pyxis Oncology
PYXS
$91.2M
| $13.8M | 0.41% |
4,184,100
| – | – |
|